Table 2 Treatment characteristics and response (n = 10)
Patient | Time (d) | Disease status prior to allo-HSCT | Type of donors | stem cell source | Conditioning regimens | CD34+ cell(× 106cells/kg) | GvHD PPx | Efficacy |
|---|---|---|---|---|---|---|---|---|
1 | 51 | PR | MMRD | Peripheral blood | TBI/Cy | 7.36 | CsA+MMF+MTX | CR |
2 | 370 | PD | MMRD | Bone marrow+peripheral blood | Bu/Cy | 0.95 | CsA+MMF+MTX | PD |
3 | 246 | PD | MMRD | Bone marrow | Bu/Cy | 3.87 | CsA+MMF+MTX | CR |
4 | 45 | PD | MMRD | Bone marrow+peripheral blood | Bu/Cy | 2.22 | CsA+MMF+MTX | CR |
5 | 101 | PD | MMRD | Bone marrow+peripheral blood | Bu/Cy | 2.64 | CsA+MMF+MTX | PD |
6 | 31 | PD | MMRD | Bone marrow+peripheral blood | TBI/Cy | 1.96 | CsA+MMF+MTX | CR |
7 | 50 | PR | MMRD | Bone marrow+peripheral blood | Bu/Cy | 5.49 | CsA+MMF+MTX | PD |
8 | 133 | PR | MSD | Peripheral blood | Bu/Cy | 3.68 | CsA+MTX | PR |
9 | 68 | PD | MMRD | Bone marrow+peripheral blood | Bu/Cy | 1.56 | CsA+MMF+MTX | PD |
10 | 119 | PD | MSD | Peripheral blood | Bu/Cy | 3.43 | CsA+MMF+MTX | CR |